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Summary.
Introduction. Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) has become a standard treatment of locally 
advanced rectal adenocarcinoma. 
Aim of the study is to analyze efficacy of neoadjuvant CRT and survival rates in patients with locally advanced rectal cancer. 
Materials and methods. Retrospective study of 60 locally advanced rectal cancer patients who underwent neoadjuvant radiotherapy 
with or without addition of neoadjuvant chemotherapy in Clinic of Oncology of Pauls Stradiņš Clinical University Hospital from 2007 
to 2012 was done. 
Results. Long-course radiotherapy (45-50.4 Gy) received 52 patients. Median time from diagnosis to radiotherapy was 35.8 days. 
Median time to surgery was 47.7 days. Pathological complete remission (pCR) of the primary rectal cancer was not observed. 
Distribution by pathologic staging was as follows: 28.8% Stage I (7.7% T1N0M0), 32.7% Stage II and 38.5% Stage III. Downstaging 
occurred in 93.7% in concomitant chemoradiation with Ftorafur, 61.9% in combination with 5FU/LV, and 53.3% in radiation without 
chemotherapy. Median PFS and OS were not met. In median follow up of 22.6 month overall survival was 90.3%, and PFS – 88%. 
Conclusions. Addition of chemotherapy to neoadjuvant radiotherapy is increasing tumor downstaging rate. Ftorafur in concomitant 
neoadjuvant chemoradiation showed increased downstaging compared to standard 5FU therapy. Response to preoperative therapy 
improves survival in patient with locally advanced rectal cancer.
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Modern neoadjuvant concurrent CRT regimens have 
consistently demonstrated pathological complete 
remission (pCR) in 10% to 20% (7). Pathologic stage 
is the most reliable predictor of survival in patients 
undergoing neoadjuvant CRT and surgery. The degree of 
tumor regression and downstaging has been correlated 
to long-term survival outcomes. The pCR is associated 
with a very favorable prognosis (6,8,9).
AIM OF THE STUDY
The aim of study is to characterize downstaging of tumor 
and survival data in patients with locally advanced rectal 
cancer after neoadjuvant radiotherapy with or without 
addition of chemotherapy.
MATERIALS AND METHODS
Between January 2007 and December 2012 167 
patients received adjuvant, neoadjuvant or palliative 
radiotherapy for rectal cancer at the Pauls Stradiņš 
Clinical University Hospital. 
A retrospective review included 60 patients with 
histologically confirmed locally advanced rectal cancer 
who received neoadjuvant radiotherapy with or without 
addition of fluoropyrimidines based chemotherapy. 
Patients who were not considered for surgical treatment 
at the end of radiotherapy were excluded.8 patients 
(13.3%) received short-course (5 x 5Gy) neoadjuvant 
radiotherapy – 1 patient in 2011, 1 patient in 2010 and 
6 patients in 2007. These patients were excluded from 
further analysis.
INTRODUCTION
Rectal cancer is one of the most common cancers. About 
450 patients (20 per 100.000 inhabitants) are diagnosed 
in Latvia every year, 55% of patients are considered 
locally advanced disease (stage II-III)(5).
Preoperative radiotherapy with conventional protracted 
fractionation (45-50.4 Gy in daily fractions of 1.8 – 
2 Gy during 5-6 weeks) with concurrent venous 
5-fluorouracil (5-FU) followed by surgery at 4-8 weeks 
is a standard treatment of locally advanced rectal cancer 
in the last 10 years. Neoadjuvant chemoradiation(CRT) 
reduces tumor volume, increases complete R0 resection, 
improves local control and overall survival in advanced 
rectal cancer patients.Neoadjuvant CRT is more effective 
than adjuvant therapy in reducing local recurrence and 
in minimizing toxicity (10). Still there are situations in 
daily practice when patient’s treatment is started with 
urgent surgery due to bowel obstruction or perforation. 
In these cases there are place for postoperative adjuvant 
CRT.
The most frequently used chemotherapy agent is 
venous 5-FU in continuous or short infusions. Oral 
fluoropyrimidines (Ftorafur, Capecitabine) have been 
developed as a therapeutic alternative of 5-FU, and 
have been shown similar efficacy and tolerability in the 
combined preoperative treatment (2,4).
The status of down staged pathologic stage after 
neoadjuvant chemoradiation is an important factor for 
oncologic outcomes.
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Data were retrieved from each patient’s medical 
records, and included radiotherapy and chemotherapy 
information, clinical and pathological TNM stage, long-
term outcome – progression free survival (PFS) and 
overall survival (OS).
Overall survival and progression free survival rates were 
estimated by the Kaplan-Meier method. The log-rank 
test was used to calculate any significant difference 
between the subgroups by univariate analysis. 
Significance levels were set at p< 0.05. All statistical 
analyses were performed by MedCalc.
RESULTS
Long-course radiotherapy (45-50.4 Gy) received 52 
patients, 37 patients (71.2%) received combined 
chemoradiation – 16 patients (43.2%) Ftorafur p/o 400-
1200 mg/d (daily during radiotherapy) and 21 patients 
(56.8%) short infusions with 5FU/LV (5FU 425 mg/m2 
and leucovorin 20 mg/m2 bolus d1-5 two cycles during 
radiotherapy).
Patients included 25 females and 27 males with a median 
age at diagnosis of 62.7 years (range, 34-82 years). 
Median time from diagnosis to radiotherapy was 35.8 
days (95% CI 23.3-46.9 days)
Median time from the end of radiotherapy to operation 
was 47.3 days (95% CI 38.0-49.9 days).
Local treatment response assessment. Clinical and 
pathological TNM data were available for all 52 patients. 
Pathological complete remission (pCR) of the primary 
rectal cancer was not observed in this study.
Patient distribution by clinical and pathological staging 
is shown in Table 1.
Downstaging occurred in category T or N, or both in 36 
patients (69.2%), in category T – 21 patients (40.4%), 
but in category N – 27 patients (51.9%). Tumor AJCC 
stage downstaging occurred in 27 patients (51.9%) 
(p<0.0001). (Table 1)
37 patients received combined chemoradiation – 
21patients received venous 5-FU/LV, 16 patients – 
Ftorafur per oral treatment. Downstaging occurred in 
75.7% patients, compared to 53.3% in patients received 
neoadjuvant radiotherapy without chemotherapy. 
Subgroup analysis reviewed a 93.7% downstaging 
in patients received Ftorafur and 61.9% in patients 
received 5FU combined treatment (Table 2).
In 33 patient (63.5%) time from the end of radiotherapy 
to surgery was >42 days (6 weeks). In this group total 
downstaging rate were 66.7%, compared to 63.1% in 
patient group with early surgery (<42 days) (p=ns).
Outcomes. Survival data for all 52 patients were 
available.
With a median follow up of 22.6 months (3-60 months), 
9 cancer relapses were identified (17.3% of all patients) – 
only local relapse in one patient, distant metastases 
in 5 patients and both local relapse and metastases in 
3 patients. The median for disease-free survival and 
overall survival had not been reached yet.
In all patient group progression free survival (PFS) at 
median follow-up of 22.6 months was 88%, but overall 
survival (OS) was 90.3%. The median PFS and OS were 
not met. (Fig.1 and Fig.2)
There was seen improvement in PFS in patients with 
downstaging in T category –no progression was observed 
at median follow up 22.6 months (PFS at 22.6 months 
100%). In patients without T category improvement, 
actuarial PFS at 22.6 months was 76.2%. (p=0.0409)
(Fig.3).
Similarly, the addition of chemotherapy improve overall 
survival – 3 year overall survival in chemoradiotherapy 
group was 83.8%, but in radiotherapy only group - 
67.2% (p=ns) (Fig.4)
In node positive (pT
any
N1-2) stage III patients PFS at 
median follow-up of 22.6 months (was 72.9% (mPFS 
36 months), but in stage I (T1-2N0) patients – 100% 
(Fig.5, Fig.6).
In patients without cancer downstaging after 
neoadjuvant treatment (downstaging in T or N, or both 
categories) PFS at median follow up of 22.6 months was 
73.3% (mPFS 35 months), but in patients with observed 
cancer downstaging - 92.2% (Fig.7)
DISCUSSION
In this retrospective study we demonstrated our 
experience in rectal cancer neoadjuvant treatment. 
Fluoropyrimidines based(venous 5FU, Capecitabine, 
Ftorafur) neoadjuvant chemoradiation is widely used 
in clinical practice in patient with locally advanced 
rectal cancer. The main priority is to achieve maximum 
tumor regression without increased toxicity. The most 
frequently used fluoropyrimidines in CRT settings are 
venous 5FU. However, infusional regimens are time-
consuming, inconvenient and uncomfortable for the 
patient, and require regular hospital visits and sometimes 
hospitalization. They are also often associated with 
venous access-related
complications such as infection, sepsis, thrombosis and 
blockage. Therefore, efforts have been made to identify 
alternative strategies to 5FU in this setting. The use of 
oral fluoropyrimidines such as Ftorafur has the potential 
to represent an appealing alternative. Ftorafur alone and 
combined with radiotherapy has not been sufficiently 
developed as a neoadjuvant treatment of rectal cancer, 
and our study provides important information of 
this setting. Preliminary results have been described 
previously in clinical case-control studies revealed low 
toxicity and high downstaging rates (2,3,4).
In preoperative radiotherapy without chemotherapy 
and delayed surgery downstaging rates of 18% have 
been reported (1). However, preoperative CRT achieves 
downstaging rates of 65% (2,11). In our study, 
downstaging (T or N, or both) was observed in 75.7% of 
the patients received 5FU containing CRT and in 93.7% 
of patients received Ftorafur containing CRT , which 
compares favorably with the best results of preoperative 
CRT with venous 5FU.
28.8% of patients achieved the earliest stage (Stage I), 
but complete pathological remission was not achieved 
in this study.
We found that survival outcomes after preoperative 
chemoradiotherapy for locally advanced rectal cancer 
are correlated with treatment response. Final pathologic 
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stage is an early response indicator for long-term 
outcomes that provides better prognostication than does 
the clinical stage. Patients who achieve pathological 
stage I have excellent prognosis with low risk for local 
or distant recurrence.
The inclusion of different multimodal treatments into 
the surgical oncologic concept,adapted to the tumor 
location and stage and to an individual patient’s risk 
factors, is mandatory. In the future, clinicopathological 
and molecular features as well as accurate preoperative 
imagingwill take an important and integrative part in 
multimodality treatment of rectal cancer.
CONCLUSIONS
1. Addition of chemotherapy to neoadjuvant 
radiotherapy is increasing tumor downstaging rate.
2. Ftorafur in concomitant neoadjuvant 
chemoradiotherapy showed increased downstaging 
compared to standard venous 5FU/LV therapy.
3. Response to preoperative therapy (pathological 
stage) improves survival in patient with locally 
advanced rectal cancer.
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All patients Stage I 2 (3.9%) 15 (28.8%)
Stage II 6 (11.5%) 17 (32.7%) p<0.0001
Stage III 44 (84.6%) 20 (38.5%)
Table 2. Downstaging in T category and N category 


















T or N 8 (53.3) 13 (61.9) 15 (93.7) p=0.03
T 6 (40) 6 (28.6) 9 (56.2) p=ns
N 5 (33.3) 11 (52.4) 11 (68.7) p=ns
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Fig. 3. Progression free survival, according to T 
downstaging. (p=0.0409; HR 3.73; 95% CI 1.0558-
13.2318 (n=52))
Fig. 4. Overall survival, according to addition 
of chemotherapy to radiotherapy; 3yOS 83.8% 
in chemoradiotherapy group, 3yOS 67.2% in 
radiotherapy only group; p=0.09, HR 2.57, 95%CI 
0.84-7.85 (n=52) 
Fig. 1. Progression free survival. Median PFS: not 
met. At median follow-up of 22.6 months PFS 
88% (n=52)
Fig. 2. Overall survival. Median OS: not met. At 
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Fig. 5. PFS according to pathological node status. 
Median PFS in pN1-2 patients - 36 month. PFS at 
median follow-up 22.6 months in node positive 
patients 72.9%, but in node negative patients 
96.2%. (p=0.048; HR 0.29; 95%CI 0.09-0.98)
Fig. 7. PFS according to cancer downstaging in T or 
N, or both categories. In patients without cancer 
downstaging after neoadjuvant treatment PFS 
at median follow up of 22.6 months was 73.3% 
(mPFS 35 months), but in patients with cancer 
downstaging 92.2%. (p=0.08; HR 3.11; 95%CI 0.84-
11.53)
 
Fig. 6. PFS according to pathological stage. In 
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